VIVUS' MUSE Now Approved in Canada; MUSE Available in 15 Countries -- 8 International Launches Completed
Business Wire - August 17, 1998 10:19
MOUNTAIN VIEW, Calif.--(BW HealthWire)--Aug. 17, 1998--VIVUS, Inc. (NASDAQ:VVUS) today announced that MUSE(R) (alprostadil) has been approved in Canada, New Zealand and Hong Kong, and approved and launched in Singapore, Thailand and the Philippines.
In addition, MUSE has now been launched in Argentina, Brazil, Sweden, Switzerland and Mexico as well as the United Kingdom, South Africa, South Korea and the United States.
"We believe that MUSE is experiencing success in gaining regulatory approvals around the globe due to the collaborative efforts of VIVUS and its partners. VIVUS also believes that the size, strength and experience of our partners Astra and Janssen, will enable successful launches in their respective territories," said Leland Wilson, CEO and President, VIVUS, Inc. "We are also pleased to report that the approval of MUSE in Canada will result in a $2 million milestone payment from Janssen Pharmaceutica."
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as MUSE(R) (alprostadil). This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacological agents via the urethra.
Note to editors: MUSE is a registered trademark of VIVUS, Inc. Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
CONTACT: VIVUS
Nina W. Ferrari, 650/934-5200
------------------------------------------------------------------------
%VIVUS VVUS |
